Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Visanne

Phase 3Small molecule

Visanne is one of 41 small molecule programs targeting Endometriosis. It is currently in Phase 3.

1

Indications

4

Total Trials

0

Active Trials

40

Competitors

Pipeline

Status by Indication[3][1]

Indication

EndometriosisActive, not recruiting

EndometriosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

199 competitors in Endometriosis

#DrugCompanyPhaseTrials

Orilissa

Lupron

Revia

Leuprorelin

Lupron

EEastern Cooperative Oncology Group

Trental

VValidus Pharmaceuticals

Firmagon

Estradiol/norethindrone Acetate

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

EE20/DRSP(BAY86-5300)

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Endometriosis2 trials

Safety and Efficacy of SH T00660AA in Treatment of Endometriosis

Completed· Bayer logo

Bayer·Phase 3·NCT00225186·168 enrolled

Efficacy and Safety of SH T00660AA in Treatment of Endometriosis

Completed· Bayer logo

Bayer·Phase 3·NCT00225199·198 enrolled

Quality of Life1 trial

Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life

Completed· Bayer logo

Bayer··NCT01595724·3,006 enrolled

Unspecified1 trial

Goserline Acetate VS Dienogest in Endometriosi

Unknown status·MMansoura University·Phase 4·NCT05013242·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Visanne. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Visanne compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Visanne. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

Related News